Skip to main content
Top
Published in: Annals of Surgical Oncology 11/2010

01-11-2010 | Melanomas

The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma

Authors: Rajmohan Murali, MBBS, Marc D. Moncrieff, MD, Jonathan Hong, MBBS, Caroline L. Cooper, MBBS, Meena V. Shingde, MBBS, David G. Samuel, MBBS, John F. Thompson, MD, Richard A. Scolyer, MD

Published in: Annals of Surgical Oncology | Issue 11/2010

Login to get access

Abstract

Background

Tumor mitotic rate (MRP) is an independent prognostic factor in clinically localized primary cutaneous melanoma, but the prognostic importance of mitotic rate in melanoma recurrences (MRR) is not known. In this study, we sought to determine the prognostic value of MRR and other clinicopathologic factors in recurrent melanoma.

Methods

Patients with primary cutaneous melanoma diagnosed between 1979 and 2006, who subsequently developed recurrence(s), were studied. Histologic sections of primary and first locoregional recurrences of melanoma were examined, and MRP and MRR were measured. Relationships between MRR, known prognostic parameters in melanoma, time to first recurrence (TTR), and postrecurrence survival were analyzed.

Results

A total of 279 patients (172 men, 107 women) had AJCC stage I (n = 97) or stage II (n = 182) melanoma. Median MRP and MRR were 4/mm2 (0–34) and 4/mm2 (0–51), respectively. There was weak association between MRP and MRR (R 2 = 0.02, p = 0.02). Independent predictors of poorer postrecurrence survival were shorter TTR (hazard ratio, 0.74; 95% confidence interval, 0.61–0.90, p = 0.003) and recurrence type (10-year postrecurrence survival for local, lymph node, and in-transit recurrences: 70%, 21.5%, and 11.1%, respectively; p = 0.04). MRR >0 was associated with poorer 10-year postrecurrence survival (39.1%) than if MRR = 0 (51.2%), but the difference did not reach statistical significance (p = 0.15). However, the difference in survival between patients with MRR >0 and those with MRR = 0 increased with time.

Conclusions

TTR is an independent predictor of postrecurrence survival. Because survival in patients with MRR >0 decreases with time (relative to those with MRR = 0), MRR should be routinely measured so that future studies can determine whether MRR has any independent predictive value.
Literature
1.
go back to reference Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97(6):1488–98.CrossRefPubMed Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97(6):1488–98.CrossRefPubMed
2.
go back to reference Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11(4):426–33.CrossRefPubMed Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11(4):426–33.CrossRefPubMed
3.
go back to reference Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.CrossRefPubMed Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.CrossRefPubMed
4.
go back to reference Bogunovic D, O’Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106(48):20429–34.CrossRefPubMed Bogunovic D, O’Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106(48):20429–34.CrossRefPubMed
5.
go back to reference Hilsenbeck SG, Allred DC. Improved methods of estimating mitotic activity in solid tumors. Hum Pathol. 1992;23(6):601–2.CrossRefPubMed Hilsenbeck SG, Allred DC. Improved methods of estimating mitotic activity in solid tumors. Hum Pathol. 1992;23(6):601–2.CrossRefPubMed
6.
go back to reference McGovern VJ, Cochran AJ, Van der Esch EP, et al. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986;18(1):12–21.CrossRefPubMed McGovern VJ, Cochran AJ, Van der Esch EP, et al. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986;18(1):12–21.CrossRefPubMed
7.
go back to reference Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.
8.
go back to reference Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15(5):1476–84.CrossRefPubMed Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15(5):1476–84.CrossRefPubMed
9.
go back to reference Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, et al. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol. 1999;38(5):549–57.CrossRefPubMed Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, et al. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol. 1999;38(5):549–57.CrossRefPubMed
10.
go back to reference Soong SJ, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67(4):228–33.CrossRefPubMed Soong SJ, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67(4):228–33.CrossRefPubMed
11.
go back to reference Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg. 1992;28(1):45–9.CrossRefPubMed Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg. 1992;28(1):45–9.CrossRefPubMed
12.
go back to reference Cruse CW, Wells KE, Schroer KR, Reintgen DS. Etiology and prognosis of local recurrence in malignant melanoma of the skin. Ann Plast Surg. 1992;28(1):26–8.CrossRefPubMed Cruse CW, Wells KE, Schroer KR, Reintgen DS. Etiology and prognosis of local recurrence in malignant melanoma of the skin. Ann Plast Surg. 1992;28(1):26–8.CrossRefPubMed
13.
go back to reference Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg. 1993;91(1):94–8.CrossRefPubMed Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg. 1993;91(1):94–8.CrossRefPubMed
14.
go back to reference Markowitz JS, Cosimi LA, Carey RW, et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg. 1991;126(6):703–7 (discussion 707–8).PubMed Markowitz JS, Cosimi LA, Carey RW, et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg. 1991;126(6):703–7 (discussion 707–8).PubMed
15.
go back to reference Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147(1):62–70.CrossRefPubMed Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147(1):62–70.CrossRefPubMed
16.
go back to reference Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27(12):1571–6.CrossRefPubMed Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27(12):1571–6.CrossRefPubMed
Metadata
Title
The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma
Authors
Rajmohan Murali, MBBS
Marc D. Moncrieff, MD
Jonathan Hong, MBBS
Caroline L. Cooper, MBBS
Meena V. Shingde, MBBS
David G. Samuel, MBBS
John F. Thompson, MD
Richard A. Scolyer, MD
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1078-0

Other articles of this Issue 11/2010

Annals of Surgical Oncology 11/2010 Go to the issue